Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib

References

• Molica S. Sex differences in incidence and outcome of chronic lymphocytic leukemia patients. Leuk Lymphoma. 2006;47:1477‐1480.
   Web of Science ®Google Scholar
• Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019;94(11):1266–1287.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760.
   PubMed Web of Science ®Google Scholar
• Molica S, Brugiatelli M, Morabito F, et al. Treatment of elderly patients with chronic lymphocytic leukemia: an unmet clinical need. Expert Rev Hematol. 2013;6(4):441–449.
   PubMed Web of Science ®Google Scholar
• Yosifov DY, Wolf C, Stilgenbauer S, et al. From biology to therapy: the CLL success story. Hemasphere. 2019;3(2):e175.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–322.
   PubMed Web of Science ®Google Scholar
• Fürstenau M, Hallek M, Eichhorst B. Sequential and combination treatments with novel agents in chronic lymphocytic leukemia. Haematologica. 2019;104(11):2144–2154.
   PubMed Web of Science ®Google Scholar
• Molica S, Matutes E, Tam C, et al. Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on. Hematol Oncol. 2019;1–8. doi: 10.1002/hon.2695. [Epub ahead of print].
   Web of Science ®Google Scholar
• Rossi D, Terzi-di-Bergamo L, De Paoli L, et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood. 2015;126(16):1921–1924.
   PubMed Web of Science ®Google Scholar
• Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208–215.
   PubMed Web of Science ®Google Scholar
• Thompson PA, Tam CS, O’Brien SM, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127(3):303–309.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–2528.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432–443.
   PubMed Web of Science ®Google Scholar
• Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicenter, randomized, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43–56.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS), a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17:200–211.
   PubMed Web of Science ®Google Scholar
• Fraser G, Cramer P, Demirkan F, et al. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia. 2019;33(4):969–980.
   PubMed Web of Science ®Google Scholar
• Fischer K, Al‑Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–2236.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.
   PubMed Web of Science ®Google Scholar
• Brown JR, Hillmen P, O’Brien S, et al. Extended follow-up and impact of high risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia. 2018;32(1):83–91.
   PubMed Web of Science ®Google Scholar
• Thompson PA, O’Brien SM, Wierda WG, et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 2015;121(20):3612–3621.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–223.
   PubMed Web of Science ®Google Scholar
• UK CLL Forum. Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients. Haematologica. 2016;101(12):1563–1572.
   PubMed Web of Science ®Google Scholar
• Winqvist M, Asklid A, Andersson PO, et al. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the swedish chronic lymphocytic leukemia group. Haematologica. 2016;101(12):1573–1580.
   PubMed Web of Science ®Google Scholar
• Ghia P, Cuneo A. Ibrutinib in the real world patient: many lights and some shades. Haematologica. 2016;101(12):1448–1450.
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Furman RR, Coutre SE, et al. Five-Year Experience with single-agent ibrutinib in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia. [ Abstract]. Blood. 2016;128(22):233.
   Web of Science ®Google Scholar
• Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323–332.
   PubMed Web of Science ®Google Scholar
• Tam CS, Trotman J, Opat S, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134(11):851–859.
   PubMed Web of Science ®Google Scholar
• Walter HS, Rule SA, Dyer MJ, et al. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016;127(4):411–419.
   PubMed Web of Science ®Google Scholar
• Awan FT, Schuh A, Brown JR, et al. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv. 2019;3(9):1553–1562.
   PubMed Web of Science ®Google Scholar
• Binnerts ME, Otipoby KL, Hopkins BT. SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wide type BTK and BTK with an acquired resistance mutation. [ Abstract]. Mol Cancer Ther. 2015;14: C186.
   Google Scholar
• Brandhuber B, Gomez E, Smith S. LOXO-305, a next generation reversible BTK inhibitor, for overcoming acquired resistance to irreversible BTK inhibitors. [ Abstract]. Clin Lymphoma Myeloma Leuk. 2018;18: S216.
   Web of Science ®Google Scholar
• Reiff SD, Mantel R, Smith LL, et al. The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and Richter transformation. Cancer Discov. 2018;8:1300–1315.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency–Appendix 4 to the guideline on the evaluation of anticancer medicinal products in man-condition specific guidance. EMA/CHMP/703715/2012 Rev. 2. [cited 2019 Dec 3]. Available from: https://www.ema.europa.eu/en/appendix-4-guideline-evaluation-anticancer-medicinal-products-man-condition-specific-guidance
   Google Scholar
• Jain N, Thompson PA, Burger JA, et al. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (GA101) (iFCG) for previously untreated patients with chronic lymphocytic leukemia (CLL) with mutated IGHV and non-del (17p). [ Abstract]. J Clin Oncol. 2017;35(1):7522.
   Google Scholar
• Davids MS, Brander DM, Kim HT, et al. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2019;6(8):e419–e428.
   PubMed Web of Science ®Google Scholar
• Kater AP, Seymour JF, Hillmen P, et al. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol. 2019;37(4):269–277.
   PubMed Web of Science ®Google Scholar
• Thompson PA, Wierda WG. Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. Blood. 2016;127(3):279–286.
   PubMed Web of Science ®Google Scholar
• Genevier HC, Hinshelwood S, Gaspar HB, et al. Expression of Bruton’s tyrosine kinase protein within the B cell lineage. Eur J Immunol. 1994;24:3100–3105.
   PubMed Web of Science ®Google Scholar
• Satterthwaite AB, Witte ON. The role of Bruton’s tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev. 2000;175:120–127.
   PubMed Web of Science ®Google Scholar
• Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107:13075–13080.
   PubMed Web of Science ®Google Scholar
• Munir T, Brown JR, O’Brien S, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353–1363.
   PubMed Web of Science ®Google Scholar
• Coutré SE, Byrd JC, Hillmen P, et al. Long- term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019;3(12):1799–1807.
   PubMed Web of Science ®Google Scholar
• Dickerson T, Wiczer T, Waller A, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019;134(22):1919–1928.
   PubMed Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437.
   PubMed Web of Science ®Google Scholar
• Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2019 Oct 18. doi: 10.1038/s41375-019-0602-x. Epub ahead of print.
   Google Scholar
• Burger JA, Sivina M, Jain N, et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019;133(10):1011–1019.
   PubMed Web of Science ®Google Scholar
• Langerbeins P, Bahlo J, Rhein C, et al. Ibrutinib versus placebo in patients with asymptomatic, treatment-naïve early stage chronic lymphocytic leukemia (CLL): primary endpoint results of the phase 3 double-blind randomized CLL12 trial. [ Abstract]. EHA Lib. 2019;273255:LB2602.
   Google Scholar
• Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1(1):80–87.
   PubMed Web of Science ®Google Scholar
• Woyach JA. How I manage ibrutinib-refractory chronic lymphocytic leukemia. Blood. 2017;129(10):1270–1274.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Guinn D, et al. BTKC481S- mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017;35(13):1437–1443.
   PubMed Web of Science ®Google Scholar
• Quinquenel A, Fornecker LM, Letestu R, et al. Prevalence of BTK and PLCG2 mutations in a real‑life CLL cohort still on ibrutinib after three years: a FILO group study. Blood. 2019;134(7):641–644.
   PubMed Web of Science ®Google Scholar
• Molica S, Giannarelli D, Baumann T, et al. Ibrutinib as initial therapy in chronic lymphocytic leukaemia: a systematic review and meta-analysis. Eur J Haematol. 2020 Jan 20. doi: 10.1111/ejh.13387. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Ma S, Kipps TJ, et al. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood. 2019;134(2):111–122.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Rawstron AC, Brock K, et al. Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study. J Clin Oncol. 2019;37(30):2722–2729.
   PubMed Web of Science ®Google Scholar
• Jain N, Keating M, Thompson P, et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019;380(22):2095–2103.
   PubMed Web of Science ®Google Scholar
• Tam CS, Siddiqi T, Allan JN, et al. Ibrutinib (Ibr) plus venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): results from the MRD cohort of the Phase 2 CAPTIVATE study. Blood. 2019;134(1):35.
   Google Scholar
• Davids MS, Kim HT, Nicotra A, et al. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. Lancet Haematol. 2019;6(1):e38–e47.
   PubMed Web of Science ®Google Scholar
• Nastoupil LJ, Lunning MA, Vose JM, et al. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematol. 2019;6(2):e100–e109.
   PubMed Web of Science ®Google Scholar
• Rogers K, Huang Y, Ruppert AS, et al. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia. Blood. 2018;132(15):1568–1572.
   PubMed Web of Science ®Google Scholar
• Patel V, Balakrishnan K, Bibikova E, et al. Comparison of acalabrutinib, a selective bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells. Clin Cancer Res. 2017;23(14):3734–3743.
   PubMed Web of Science ®Google Scholar
• Herman SEM, Montraveta A, Niemann CU, et al. The bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia. Clin Cancer Res. 2017;23(11):2831–2841.
   PubMed Web of Science ®Google Scholar
• Ghia P, Pluta A, Wach M, et al. ASCEND phase 3 study of acalabrutinib vs investigator’s choice of rituximab plus idelalisib (IDR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). [ Abstract]. EHA Lib. 2019;LB2606.
   Google Scholar
• Sharman JP, Banerji V, Fogliatto LM, et al. ELEVATE TN: phase 3 study of acalabrutinib combined with obinutuzumab (O) or alone Vs O plus chlorambucil (Clb) in patients (Pts) with treatment-naive chronic lymphocytic leukemia (CLL). [ Abstract.] Blood. 2019;134(S1):31.
   Google Scholar
• Woyach J, Huang Y, Rogers K, et al. Resistance to acalabrutinib in CLL is mediated primarily by BTK mutations. [ Abstract]. Blood. 2019;134(S1):504.
   Google Scholar
• Patel VK, Lamothe B, Ayres ML, et al. Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia. 2018;32(4):920–930.
   PubMed Web of Science ®Google Scholar
• Lampson BL, Tyekucheva S, Crombie JL, et al. Preliminary safety and efficacy results from a phase 2 study of acalabrutinib, venetoclax and obinutuzumab in patients with previously untreated chronic lymphocytic leukemia (CLL). [ Abstract]. Blood. 2019;134(S1):32.
   Google Scholar
• Munakata W, Ando K, Hatake K, et al. Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan. Cancer Sci. 2019;110(5):1686–1694.
   PubMed Web of Science ®Google Scholar
• Cull G, Simpson D, Opat S, et al. Treatment with the bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrates high overall response rate and durable responses in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): updated results from a Phase 1/2 Trial. [ Abstract]. Blood. 2019;134(S1):500.
   PubMedGoogle Scholar
• Hillmen P, Brown JR, Byrd JC, et al. ALPINE: phase III zanubrutinib (BGB-3111) versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). [ Abstract]. J Clin Oncol. 2019;37(15):TPS7572.
   Web of Science ®Google Scholar
• Handunnetti S, Tang C, Nguyen T, et al. BTK Leu528Trp - a potential secondary resistance mechanism specific for patients with chronic lymphocytic leukemia Treated with the next generation BTK inhibitor zanubrutinib. [ Abstract]. Blood. 2019;134(S1):170.
   Google Scholar
• Tam CS, Robak T, Ghia P, et al. Efficacy and safety of zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): initial results from arm C of the Sequoia (BGB-3111-304) trial. [ Abstract]. Blood. 2019;134(S1):499.
   Google Scholar
• Reiff SD, Muhowski EM, Guinn D, et al. Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. Blood. 2018;132:1039–1049.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Smith S, Wagner-Johnston N, et al. First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget. 2018;9(16):13023–13035.
   PubMedGoogle Scholar
• Allan JN, Patel K, Mato AR, et al. Preliminary Results of a Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton’s Tyrosine Kinase Inhibitor (BTKi) Vecabrutinib in B-Cell Malignancies. [ Abstract]. EHA Lib. 2019;PS1148.
   Google Scholar
• Woyach J, Flinn I, Stephens DM, et al. A phase 1 dose escalation study of ARQ 531 in selected patients with relapsed or refractory hematologic malignancies [ Abstract]. Blood. 2018;132:3136.
   Google Scholar
• Gomez EB, Lippincott I, Rosendahal MS, et al. Loxo-305, a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations. [ Abstract]. Blood. 2019;134(S1):4644.
   Google Scholar
• Mato AR, Flinn JW, Pagel JM, et al. Results from a first-in-human, proof-of-concept Phase 1 trial in pretreated B-cell malignancies for Loxo-305, a next-generation, highly selective, non-covalent BTK inhibitor. [ Abstract]. Blood. 2019;134(S1):501.
   PubMedGoogle Scholar
• Molica S, Giannarelli D, Mirabelli R, et al. The magnitude of improvement in progression-free survival with targeted therapy in relapsed/refractory chronic lymphocytic leukemia based on prognostic risk category: a systematic review and meta-analysis. Leuk Lymphoma. 2019;60(7):1644–1649.
   PubMed Web of Science ®Google Scholar
• Baliakas P, Jeromin S, Iskas M, et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood. 2019;133(11):1205–1216.
   PubMed Web of Science ®Google Scholar
• Barr PM, Brown JR, Hillmen P, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017;129(19):2612‐2615.
   Web of Science ®Google Scholar
• Ahn IE, Basumallik N, Tian X, et al. Clinically-indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL. Blood. 2019;133(22):2452–2455.
   PubMed Web of Science ®Google Scholar
• Akhtar OS, Attwood K, Lund I, et al. Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2019;60(7):1650–1655.
   PubMed Web of Science ®Google Scholar
• Mato AR, Timlin C, Ujjani C, et al. Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study. Br J Haematol. 2018;181(2):259–261.
   PubMed Web of Science ®Google Scholar
• Chen LS, Bose P, Cruz ND, et al. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood. 2018;132(21):2249–2259.
   PubMed Web of Science ®Google Scholar
• Bottcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30(9):980–988.
   PubMed Web of Science ®Google Scholar
• Kovacs G, Robrecht S, Fink AM, et al. Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL Study Group. J Clin Oncol. 2016;34(31):3758–3765.
   PubMed Web of Science ®Google Scholar
• Molica S, Giannarelli D, Montserrat E. Minimal residual disease and survival outcomes in patients with chronic lymphocytic leukemia: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2019;19(7):423–430.
   PubMed Web of Science ®Google Scholar
• Ahn IE, Farooqui MZH, Tian X, et al. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood. 2018;131(21):2357–2366.
   PubMed Web of Science ®Google Scholar
• Yazdy MS, Mato AR, Cheson B. Combinations or sequences of targeted agents in CLL: is the whole greater than the sum of its parts (Aristotle, 360 BC)? Blood. 2019;133(2):121–129.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Project orbis: FDA approves acalabrutinib for CLL and SLL. [ cited 2019 Nov 26]. Retrieved from: https://www.fda.gov/drugs/resources-information-approved-drugs/project-orbis-fda-approves-acalabrutinib-cll-and-sll
   Google Scholar